Premium
Hollow ZnO Nanospheres Enhance Anticancer Immunity by Promoting CD4 + and CD8 + T Cell Populations In Vivo
Author(s) -
Wang Xiupeng,
Li Xia,
Ito Atsuo,
Sogo Yu,
Watanabe Yohei,
Tsuji Noriko M.
Publication year - 2017
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201701816
Subject(s) - cancer immunotherapy , adjuvant , in vivo , cancer research , immunotherapy , t cell , antigen , cd8 , cancer cell , cytotoxic t cell , cancer , population , materials science , chemistry , immunology , immune system , in vitro , medicine , biology , biochemistry , microbiology and biotechnology , environmental health
Appropriate adjuvant aiding in generating robust anticancer immunity is crucial for cancer immunotherapy. Herein, hollow ZnO (HZnO) nanospheres are synthesized by a facile method using carbon nanospheres as the template. The HZnO nanospheres significantly promote the cellular uptake of a model antigen, and cytokine secretion by antigen‐presenting cells in vitro. HZnO loaded with ovalbumin and polyinosinic‐polycytidylic acid (poly(I:C)) inhibits cancer growth and metastasis to inguinal lymph node in a cancer cell challenge model. Moreover, HZnO loaded with autologous cancer antigens inhibits cancer cell growth in a cancer cell re‐challenge model. HZnO nanospheres significantly improve the CD4 + and/or CD8 + T cell population in splenocytes of mice in both cancer cell challenge model and re‐challenge model. The HZnO nanospheres can be used for cancer immunotherapy as adjuvant.